BPL Medical Technologies Aims to Develop One-Third of Products In-House by 2030.

BPL Medical Technologies, a veteran in the medical devices sector, is embarking on a strategic shift to become an innovation-driven manufacturing company. The company aims to increase its share of products developed in-house from the current 20% to at least 35% by 2030, according to Managing Director Shravan Subramanyam.

Subramanyam, who took the helm in April, described the move as a transformation from a "trading company to an innovative manufacturing company." The company's goal is to develop "significant own products and IP (intellectual property) driven innovation." This will be achieved through a mix of in-house development and strategic collaborations.

Ambitious Growth and Expansion

With two manufacturing facilities in Karnataka and Kerala, BPL Medical Technologies is targeting revenue of approximately ₹600 crore by the end of March 2026, up from ₹500 crore in the previous year. The company's long-term growth strategy includes organic expansion, licensing deals, and potential acquisitions.

Subramanyam acknowledged that the biggest challenge is "completely changing the DNA of the organisation" to focus on innovation. Ultimately, the company aims to leverage its strengthened manufacturing and assembly capabilities to serve markets beyond India.